Bexson Logo - Final.png

SANTA BARBARA, Calif., May 15, 2019 – Bexson Biomedical, Inc. announced today that the company filed a provisional patent application with the United States Patent and Trademark Office, specific to its proprietary formulation of ketamine designed for subcutaneous delivery. This is the second patent family Bexson has filed describing its ketamine-based products for pain management. In November 2017 Bexson filed its first provisional use patent. The law firm Wilson, Sonsini, Goodrich & Rosati filed the applications on behalf of the company, and continues to counsel Bexson on patent strategy.


“Patients, and really our entire healthcare system, are in dire need of new non-opioid therapies for pain management,” said Gregg Peterson, Bexson’s Chief Executive Officer. “Providing solid IP protection is an important step toward making this therapy available for large-market, non-orphan diseases. We look forward to filing our non-provisional patent applications with the USPTO in the future.”


Bexson Biomedical, Inc. is a research stage company developing ketamine-based therapies for both chronic and acute pain management. Visit at: